Dawson W W, Jordan B L, Marsh R D, Hazariwala K, Flowers F P, Fang T
Department of Ophthalmology, University of Florida, Gainesville, FL 32610, USA.
Br J Ophthalmol. 2001 Mar;85(3):291-6. doi: 10.1136/bjo.85.3.291.
Profound central-retinal visual losses have been a major presenting factor reported in cancer and melanoma associated retinopathies (CAR, MAR). However, it is well established that standardised tests of peripheral retinal function are often the most sensitive detectors of early eye disease. This is a preliminary investigation of the responsiveness of the peripheral retina to "distant" (non-eye or CNS) cancers using easily obtained standardised tests.
The design is a single blind study where test results are compared with published norms and a small age matched control group. Of 120 ambulatory cancer outpatients who were interviewed at routine follow up examinations, 111 volunteered and admitted a range of mild visual changes. 25 cancer patients completed all tests of peripheral vision function and a clinical screening. There were seven control subjects of the same age range.
98% (49 of 50) of eyes from the patient cohort were judged clinically normal following examinations which emphasised the central retina, fundus appearance, and static fields. On testing which emphasised the visual periphery, 46 (92%) eyes showed one or more quantitative abnormalities >2 SD from the age adjusted norm means. These abnormalities clustered mainly about dark adaptation (rod cell) sensitivity (31, 62% of measured sites), the blue sensitive retinal cells (17, 34% of measured eyes), and the oscillatory component (OP) of the electroretinogram (23, 46% of measured eyes). One control eye (7%) showed a significant dark adaptation abnormality and ERG reduction. There was no identifiable interaction between chemotherapy mode and the cancer associated retinal deficits (CARD). Antiretinal antibodies were found in sera from most patients and controls.
CARD is common in the retinal periphery of many cancer patients, and is distinct from rare CAR, MAR central-retinal responses. CARD has numerous potential clinical uses which justify expanded research with more defined large samples.
严重的视网膜中央视觉丧失一直是癌症和黑色素瘤相关性视网膜病变(CAR、MAR)中报道的主要表现因素。然而,众所周知,视网膜周边功能的标准化测试通常是早期眼部疾病最敏感的检测方法。这是一项使用易于获得的标准化测试对外周视网膜对“远处”(非眼部或中枢神经系统)癌症的反应性进行的初步研究。
该设计为单盲研究,将测试结果与已发表的标准以及一个年龄匹配的小对照组进行比较。在常规随访检查中接受访谈的120名癌症门诊患者中,111名自愿参与并承认有一系列轻度视力变化。25名癌症患者完成了所有周边视觉功能测试和临床筛查。有7名年龄范围相同的对照受试者。
在强调视网膜中央、眼底外观和静态视野的检查后,患者队列中98%(50只眼中的49只)的眼睛临床判断正常。在强调视觉周边的测试中,46只(92%)眼睛显示出一项或多项定量异常,超过年龄调整后的正常均值2个标准差。这些异常主要集中在暗适应(视杆细胞)敏感性(31个,占测量部位的62%)、蓝色敏感视网膜细胞(17只,占测量眼睛的34%)以及视网膜电图的振荡成分(OP)(23只,占测量眼睛的46%)。一只对照眼(7%)显示出明显的暗适应异常和视网膜电图降低。化疗方式与癌症相关性视网膜缺陷(CARD)之间没有可识别的相互作用。在大多数患者和对照的血清中发现了抗视网膜抗体。
CARD在许多癌症患者的视网膜周边很常见,并且与罕见的CAR、MAR视网膜中央反应不同。CARD有许多潜在的临床用途,这证明有必要用更明确的大样本进行进一步研究。